Mettler-Toledo International, I (MTD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $11.46
- Estimate
- $10.81
- Surprise
- +6.1%
- Score at report (before → after)
- 5.6 → 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Mettler-Toledo International, I (MTD) beat the $10.81 estimate with adjusted EPS of $11.46 — a clear 6.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 5.5/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MTD Sell at 5.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.1% surprise compares with a +4.3% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (0.4% away)
- Leverage penalty (D/E 166.7): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1519.15
- Price target
- $1747.02
- Stop
- $1436.23
- Upside to target
- +15.0%
At 33.6× trailing and 28.9× forward earnings, consensus estimates imply little change in earnings power.
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
MTD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $29.90B
- P/E (fwd)
- 28.9
- P/E (ttm)
- 33.6
- 52-week range
- $1023.05–$1525.17
- Off 52-week high
- 0.4%
- RSI (14)
- 72
- Volume vs avg
- 1.19×
- Score today
- 5.4/10